Reprint

Galectins in Cancer and Translational Medicine

Edited by
November 2018
350 pages
  • ISBN978-3-03897-408-6 (Paperback)
  • ISBN978-3-03897-409-3 (PDF)

This book is a reprint of the Special Issue Galectins in Cancer and Translational Medicine that was published in

Summary

 

In the post-genomic era, many efforts have been devoted to better understanding the biological information encoded by the cell “glycome” in normal and pathologic conditions. The glycan signature of human cells plays a pivotal role in regulating fundamental biological processes, which are critical for cell physiology and for cancer as well.

Galectins (also worded S-type lectins) are an evolutionarily conserved family of endogenous lectins, which bind carbohydrates with high specificity. These molecules, which can be found both intracellularly and in the extracellular milieu, are functionally active in converting glycan-containing information into cell biological programs. This fashionable mechanism of signal transduction plays a relevant role in regulating several biological functions, including RNA splicing, gene transcription, cell migration and differentiation, apoptosis, immune response, and tumor growth and progression.

It is not surprising, indeed, that a large number of studies on galectin–glycan interactions and galectins expression and function in human diseases have been published in the recent literature, spanning from immunology to cardiovascular medicine, from diagnostic Pathology to nuclear medicine.

The aim of this Special Issue of IJMS is to collect selected contributions in the field reporting data, concepts, and new ideas, which have the potential to be translated in a clinical setting in the near future, in order to improve the diagnosis and treatment of cancer and other relevant human diseases.

Format
  • Paperback
License
© 2018 by the authors; CC BY-NC-ND license
Keywords
Galectin-1; Galectin-3; Galectin-7; ovarian cancer; overall survival; thyroid cancer; meta-analysis; cytology; Galectin-3; fine needle aspiration (FNAC); translational medicine; galectin-9; pathogenesis; treatment; viral infection; galectin-3; osteoblasts; osteoclasts; bone remodeling; vascular osteogenesis; galectin-1 inhibitor; OTX008; Avastin; Anginex; hypoxia; pimonidazole; vessel normalization; galectins; myeloma; galectin-1; galectin-3; galectin-8; galectin-9; galectins; head and neck cancer; thyroid cancer; galectins; galectin-7; epithelia; carcinoma; galectin-12; differentiation; adipogenesis; cellular plasticity; galectins; cancer; diagnosis; galectins in therapy; galectin-8; galectin-9; immunochemistry; ovarian cancer; prognostic factor; disease-free survival; overall survival; carbohydrate; galectin-3; galectins in diagnosis; galectins in therapy; glycosyltransferase; surface plasmon resonance; molecular modeling; Galectin-3; Gal-3; binding interaction; galectin; inhibitor; isothermal titration calorimetry; NMR (Nuclear Magnetic Resonance); thiodigalactoside; X-ray crystallography; galectin-1; galectin-3; galectin-9; immunotherapy; galectin inhibitors; galectin-3; thyroid cancer; thyroid FNA-cytology, tumor imaging in vivo; immuno-PET; Galectin-1; radiation response; neuroblastoma; galectins; carbohydrates; apoptosis; cell adhesion; protein structure; cancer; galectin-targeted therapeutics; galectin-3; atrial fibrillation; ablation; urinary bladder urothelial carcinoma; galectin-1; fatty acid binding protein 4; glutamine synthetase; two-dimensional gel electrophoresis; n/a